RU2676766C2 - Функционализованные соединения бензопирана и их применение - Google Patents

Функционализованные соединения бензопирана и их применение Download PDF

Info

Publication number
RU2676766C2
RU2676766C2 RU2016133731A RU2016133731A RU2676766C2 RU 2676766 C2 RU2676766 C2 RU 2676766C2 RU 2016133731 A RU2016133731 A RU 2016133731A RU 2016133731 A RU2016133731 A RU 2016133731A RU 2676766 C2 RU2676766 C2 RU 2676766C2
Authority
RU
Russia
Prior art keywords
compound
cancer
group
formula
compounds
Prior art date
Application number
RU2016133731A
Other languages
English (en)
Russian (ru)
Other versions
RU2016133731A (ru
RU2016133731A3 (enExample
Inventor
Эндрю ХИТОН
Дэвид БРАУН
Грэхем КЕЛЛИ
Original Assignee
Новоген Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новоген Лимитед filed Critical Новоген Лимитед
Publication of RU2016133731A publication Critical patent/RU2016133731A/ru
Publication of RU2016133731A3 publication Critical patent/RU2016133731A3/ru
Application granted granted Critical
Publication of RU2676766C2 publication Critical patent/RU2676766C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016133731A 2014-02-07 2015-02-05 Функционализованные соединения бензопирана и их применение RU2676766C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461937368P 2014-02-07 2014-02-07
US61/937,368 2014-02-07
US201461987323P 2014-05-01 2014-05-01
US61/987,323 2014-05-01
PCT/AU2015/050040 WO2015117202A1 (en) 2014-02-07 2015-02-05 Functionalised benzopyran compounds and use thereof

Publications (3)

Publication Number Publication Date
RU2016133731A RU2016133731A (ru) 2018-03-12
RU2016133731A3 RU2016133731A3 (enExample) 2018-08-08
RU2676766C2 true RU2676766C2 (ru) 2019-01-11

Family

ID=53777071

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016133731A RU2676766C2 (ru) 2014-02-07 2015-02-05 Функционализованные соединения бензопирана и их применение

Country Status (24)

Country Link
US (2) US9701655B2 (enExample)
EP (1) EP2953938B1 (enExample)
JP (1) JP6570042B2 (enExample)
KR (1) KR102395543B1 (enExample)
CN (2) CN105980372B (enExample)
AU (1) AU2015213484B2 (enExample)
BR (1) BR112016018099B8 (enExample)
CA (1) CA2936012C (enExample)
CL (1) CL2016001937A1 (enExample)
DK (1) DK2953938T3 (enExample)
ES (1) ES2643407T3 (enExample)
IL (1) IL241515B (enExample)
LT (1) LT2953938T (enExample)
MX (1) MX368063B (enExample)
MY (1) MY195739A (enExample)
NZ (1) NZ711603A (enExample)
PH (1) PH12016501422B1 (enExample)
PL (1) PL2953938T3 (enExample)
PT (1) PT2953938T (enExample)
RU (1) RU2676766C2 (enExample)
SA (1) SA516371583B1 (enExample)
SG (2) SG11201506988TA (enExample)
SI (1) SI2953938T1 (enExample)
WO (1) WO2015117202A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201506988TA (en) * 2014-02-07 2015-10-29 Novogen ltd Functionalised benzopyran compounds and use thereof
HUE054998T2 (hu) 2015-02-02 2021-10-28 Mei Pharma Inc Kombinációs terápiák emlõrák kezelésében való alkalmazásra
US10265294B2 (en) 2016-03-31 2019-04-23 Yale University Compositions and methods for treating epithelial cancer
EP3439644B1 (en) 2016-04-06 2022-01-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
AU2017247006B2 (en) * 2016-04-06 2022-05-12 Noxopharm Limited Radiotherapy improvements
CN109730996B (zh) * 2017-03-01 2021-08-24 浙江大学 喹啉结构类型雄激素受体拮抗剂及其应用
EP4125870A1 (en) 2020-03-30 2023-02-08 Noxopharm Limited Methods for the treatment of inflammation associated with infection
WO2021252776A1 (en) * 2020-06-11 2021-12-16 Mei Pharma, Inc. Combination therapies
WO2023235929A1 (en) * 2022-06-08 2023-12-14 Noxopharm Limited Functionalised benzopyran compounds and uses thereof
CN118005594B (zh) * 2023-05-24 2024-10-29 内蒙古大学 3-羟基苯并二氢吡喃衍生物的合成及其抗肿瘤活性

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018773A1 (en) * 1996-10-28 1998-05-07 Novo Nordisk A/S Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
RU2232758C2 (ru) * 1998-09-23 2004-07-20 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием
WO2005049008A1 (en) * 2003-11-19 2005-06-02 Novogen Research Pty Ltd Combinational radiotherapy and chemotherapy compositions and methods
WO2006032086A1 (en) * 2004-09-21 2006-03-30 Novogen Research Pty Ltd Chroman derivatives, medicaments and use in therapy
WO2012061409A1 (en) * 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
US20120251630A1 (en) * 2011-03-29 2012-10-04 Marshall Edwards, Inc. Remission therapy of cancer with isoflavonoids

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US4447622A (en) 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof
BE891562A (fr) 1981-12-21 1982-04-16 Council Scient Ind Res Isomeres 1 et d de d1-3, 4-trans-3, 4-diarylchromanes 2, 2-disubstitues et leurs derives, leur preparation et leur utilisation
US5280040A (en) 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5451603A (en) 1993-03-11 1995-09-19 Zymogenetics, Inc. 3,4-diarylchromans for treatment of dermatitis
JPH10511960A (ja) 1995-01-13 1998-11-17 ノボ ノルディスク アクティーゼルスカブ 特発性の又は生理学的な女性化乳房の治療又は予防のための医薬製剤の製造のための３，４−ジフェニル・クロマンの使用
HUP9702244A3 (en) 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders
HUP9800521A3 (en) 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or propylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis
CN1168101A (zh) 1995-01-20 1997-12-17 诺沃挪第克公司 3，4-二苯基苯并二氢吡喃制备治疗或预防大脑退化性疾病的药物组合物的用途
TW448046B (en) 1995-01-20 2001-08-01 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
CA2208852A1 (en) 1995-01-20 1996-07-25 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
IL124882A0 (en) 1996-01-11 1999-01-26 Novo Nordisk As Use of 3, 4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
CN1207038A (zh) 1996-01-11 1999-02-03 诺沃挪第克公司 3,4－二苯基苯并二氢吡喃在生产预防或治疗绝经症状的药物组合物中的应用
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5756539A (en) 1996-07-11 1998-05-26 Novo Nordis A/S 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders
US5780502A (en) 1996-07-12 1998-07-14 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
US5925771A (en) 1996-10-28 1999-07-20 Novo Nordisk A/S Process for the preparation of (-)-3,4-trans-diarylchromans
US6043269A (en) 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
WO1998018771A1 (en) 1996-10-28 1998-05-07 Novo Nordisk A/S Novel (-)-enantiomers of cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US5919817A (en) 1996-10-28 1999-07-06 Novo Nordisk A/S Cis-3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
AU5550298A (en) 1997-01-29 1998-08-25 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical compositionfor increasing libido in post-menopausal women
WO1998033500A1 (en) 1997-01-29 1998-08-06 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting senescence-associated motor impairment
US6184005B1 (en) 1998-04-28 2001-02-06 Novo Nordisk A/S Enzymatic resolvation for obtaining a (−)-3,4-trans-diarylchroman
AU6315300A (en) 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
JP2004510815A (ja) 2000-10-13 2004-04-08 アストラゼネカ・アクチエボラーグ エストロゲン受容体−βリガンド
JP4256679B2 (ja) 2001-03-16 2009-04-22 ノボゲン リサーチ ピーティーワイ リミテッド 再狭窄の治療方法
US20050119301A1 (en) 2001-03-16 2005-06-02 Alan Husband Treatment of restenosis
EP1465619A1 (en) 2002-01-14 2004-10-13 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
US20040167165A1 (en) 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-7 receptor
US20060141591A1 (en) 2003-06-04 2006-06-29 Youichi Kyuuko Method for producing optically active chroman-carboxylate
JP4976649B2 (ja) * 2004-09-21 2012-07-18 マーシャル エドワーズ，インク． 化合物
NZ553834A (en) 2004-09-21 2010-03-26 Novogen Res Pty Ltd 7-hydroxy-3,4-diphenyl-chroman and chromene derivatives
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
JP4913056B2 (ja) * 2004-09-21 2012-04-11 マーシャル エドワーズ，インコーポレーテッド 置換クロマン誘導体、医薬品、および治療における使用
US7528267B2 (en) 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
US20090221564A1 (en) 2006-02-21 2009-09-03 Trigen Limited Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease
EP2084141A4 (en) 2006-10-30 2010-07-21 Novogen Res Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
CN101210012B (zh) 2006-12-31 2011-09-14 南华大学 新的含烟酸异黄酮酯衍生物及其制造方法和用途
MX2011002144A (es) 2008-08-29 2011-07-29 Novogen Res Pty Ltd Actividades inmunomoduladoras.
US20100130598A1 (en) 2008-10-22 2010-05-27 Novogen Research Pty Ltd. Methods for inducing programmed cell death
AU2008230055A1 (en) 2008-10-22 2010-05-06 Novogen Research Pty Ltd Methods for Inducing Programmed Cell Death
WO2011115819A2 (en) 2010-03-15 2011-09-22 Genus Oncology, Llc Small molecule inhibitors of muc1 and methods of identifying the same
WO2011156889A1 (en) 2010-06-14 2011-12-22 Trt Pharma Inc. Novel modulators of nrf2 and uses thereof
CN102153535A (zh) 2011-03-04 2011-08-17 中国海洋大学 一种抗肿瘤多药耐药抑制剂苯并吡喃-3-醇酯化衍生物及其制备方法和应用
US20150018566A1 (en) * 2011-08-25 2015-01-15 The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy Tubulin binding agents
CN110664816A (zh) 2012-06-07 2020-01-10 佐治亚州立大学研究基金会公司 Seca抑制剂以及其制备和使用方法
CN103408528B (zh) 2013-08-13 2015-04-29 浙江大学 一种色满化合物及其制备方法和应用
CN103450142B (zh) 2013-09-04 2015-03-25 浙江大学 一种色满化合物及其提取方法和应用
CN103585145A (zh) 2013-11-28 2014-02-19 常州科立信医疗器械有限公司 Artoxanthochromane在治疗前列腺癌药物中的应用
CN103638008B (zh) 2013-12-02 2015-09-16 刘艳娇 Artoxanthochromane在治疗皮肤癌药物中的应用
CN103690525A (zh) 2013-12-02 2014-04-02 常州科立信医疗器械有限公司 Artoxanthochromane在治疗舌癌药物中的应用
CN103705503A (zh) 2013-12-04 2014-04-09 常州科立信医疗器械有限公司 Artoxanthochromane在治疗乳腺癌药物中的应用
SG11201506988TA (en) * 2014-02-07 2015-10-29 Novogen ltd Functionalised benzopyran compounds and use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018773A1 (en) * 1996-10-28 1998-05-07 Novo Nordisk A/S Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
RU2232758C2 (ru) * 1998-09-23 2004-07-20 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием
WO2005049008A1 (en) * 2003-11-19 2005-06-02 Novogen Research Pty Ltd Combinational radiotherapy and chemotherapy compositions and methods
WO2006032086A1 (en) * 2004-09-21 2006-03-30 Novogen Research Pty Ltd Chroman derivatives, medicaments and use in therapy
WO2012061409A1 (en) * 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
US20120251630A1 (en) * 2011-03-29 2012-10-04 Marshall Edwards, Inc. Remission therapy of cancer with isoflavonoids

Also Published As

Publication number Publication date
PL2953938T3 (pl) 2017-12-29
JP2017507175A (ja) 2017-03-16
CN105980372B (zh) 2018-05-08
CN108484559A (zh) 2018-09-04
US9701655B2 (en) 2017-07-11
EP2953938A1 (en) 2015-12-16
KR20160110427A (ko) 2016-09-21
LT2953938T (lt) 2017-10-10
SG11201604490SA (en) 2016-07-28
CA2936012A1 (en) 2015-08-13
US20160340329A1 (en) 2016-11-24
DK2953938T3 (en) 2017-10-02
AU2015213484A1 (en) 2015-09-17
CL2016001937A1 (es) 2017-01-20
PT2953938T (pt) 2017-10-09
SI2953938T1 (en) 2018-01-31
SG11201506988TA (en) 2015-10-29
MX2016010137A (es) 2017-02-15
MY195739A (en) 2023-02-08
WO2015117202A1 (en) 2015-08-13
MX368063B (es) 2019-09-18
NZ711603A (en) 2017-05-26
PH12016501422B1 (en) 2022-02-16
ES2643407T3 (es) 2017-11-22
CA2936012C (en) 2023-03-07
BR112016018099A2 (pt) 2017-08-08
IL241515A0 (en) 2015-11-30
EP2953938A4 (en) 2016-08-10
SA516371583B1 (ar) 2019-04-18
RU2016133731A (ru) 2018-03-12
US10370349B2 (en) 2019-08-06
KR102395543B1 (ko) 2022-05-09
AU2015213484B2 (en) 2015-11-05
HK1218914A1 (en) 2017-03-17
EP2953938B1 (en) 2017-08-02
JP6570042B2 (ja) 2019-09-04
BR112016018099B1 (pt) 2022-10-11
US20180141925A1 (en) 2018-05-24
PH12016501422A1 (en) 2016-08-31
CN105980372A (zh) 2016-09-28
BR112016018099B8 (pt) 2023-01-17
IL241515B (en) 2019-06-30
RU2016133731A3 (enExample) 2018-08-08

Similar Documents

Publication Publication Date Title
RU2676766C2 (ru) Функционализованные соединения бензопирана и их применение
EP3229810B1 (en) Phospholipid ether analogs as cancer-targeting drug vehicles
JP2016530285A (ja) 癌の撮像及び治療のためのハロゲン化化合物、及びその使用方法
WO2019227167A1 (en) Compositions and treatments
JP2019094351A (ja) がんの処置のための医薬の組合せ
TW201609094A (zh) 治療癌症之新穎方法
US9890106B2 (en) Anti-cancer lead molecule
CN107216283B (zh) 一种含有二氢吡啶结构的β-榄香烯衍生物及其制备方法和用途
TW201132342A (en) Antrocin containing pharmaceutical compositions for inhibiting cancer cells
CN106924225A (zh) 厚朴酚在制备抗肿瘤药物增敏剂中的应用
KR20150099655A (ko) 벤조일옥시신남알데히드-폴리에틸렌글리콜 결합 마이셀에 아연 프로토포르피린을 담지한 pH 감응형 항암 전구약물 및 이의 제조방법
JP2008506684A (ja) 「抗ガン性野生チョウセンニンジンの精製エキス調整法及びそのガン融合製剤」
HK1263249A1 (en) Functionalised benzopyran compounds and use thereof
HK1218914B (en) Functionalised benzopyran compounds and use thereof
AU2015201006A1 (en) Benzopyran compounds and use thereof
KR101852054B1 (ko) 시스-3-헥센알을 포함하는, 암 줄기세포 성장 억제용 조성물
TWI723030B (zh) 二氫異丹蔘酮ｉ於治療癌症之用途
CN106890173A (zh) 2-羟基泽兰内酯在制备抗肿瘤药物增敏剂中的应用
KR20100004681A (ko) ｐ21의 발현을 증가시키는 활성을 갖는 화합물5,4'-디메톡시플라본의 항암제로서의 용도

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
QB4A Licence on use of patent

Free format text: LICENCE FORMERLY AGREED ON 20211021

Effective date: 20211021